Physician profile
Reena J Patel
NPI 1275800864
$1,276.50
in general payments reported to CMS, 2019-2025
22 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $37.67 · 2022: $239 · 2023: $165 · 2024: $146 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $162.10 | 2024-2025 | Saphnelo, Airsupra, Breztri |
| Globus Medical, INC. | $153.98 | 2025 | Senza |
| Abbott Laboratories | $99.70 | 2025 | Infinity |
| Amgen INC. | $97.12 | 2019-2025 | Krystexxa |
| Ardelyx, INC. | $75.18 | 2022-2023 | Ibsrela |
| Lilly USA, LLC | $70.94 | 2022-2025 | Mounjaro, Zepbound |
| Amneal Pharmaceuticals LLC | $50.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.49 | 2019 | |
| Pfizer INC. | $44.79 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $40.00 | 2023-2025 | Eliquis |
| Tandem Diabetes Care, INC. | $29.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dynavax Technologies Corporation | $25.05 | 2023 | Heplisav-B |
| Eisai INC. | $24.78 | 2022 | |
| Electromed, INC. | $22.88 | 2023 | Smartvest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $22.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.30 | 2025 | Jardiance |
| Janssen Biotech, INC. | $20.38 | 2023 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.03 | 2023 | Xifaxan |
| Ani Pharmaceuticals, INC. | $15.52 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $13.48 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.